This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Karo Pharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

-46.5%

Groei van de winst

-52.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	7.3%
Inkomstengroei	29.8%
Rendement op eigen vermogen	-2.3%
Nettomarge	-5.5%
Laatste winstupdate	30 Jun 2022

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Karo Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

DB:KA6N Opbrengsten, kosten en inkomsten (SEK Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 22	3,466	-190	1,935	0
31 Mar 22	3,231	-141	1,745	0
31 Dec 21	2,961	-17	1,513	0
30 Sep 21	2,921	63	1,338	0
30 Jun 21	2,861	2	1,404	0
31 Mar 21	2,802	49	1,303	0
31 Dec 20	2,883	82	1,351	0
30 Sep 20	2,811	86	1,181	0
30 Jun 20	2,575	87	1,016	0
31 Mar 20	2,274	55	842	0
31 Dec 19	1,901	9	681	0
30 Sep 19	1,715	60	673	0
30 Jun 19	1,667	117	611	0
31 Mar 19	1,769	650	581	0
31 Dec 18	1,615	657	521	1
30 Sep 18	1,391	595	445	2
30 Jun 18	1,132	551	369	2
31 Mar 18	785	40	288	3
31 Dec 17	658	15	242	4
30 Sep 17	515	141	178	3
30 Jun 17	463	133	158	5
31 Mar 17	404	114	153	5
31 Dec 16	347	96	141	5
30 Sep 16	308	-20	130	10
30 Jun 16	232	-41	110	13
31 Mar 16	151	-60	77	29
31 Dec 15	69	-78	54	35

Kwaliteitswinsten: KA6N is currently unprofitable.

Groeiende winstmarge: KA6N is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: KA6N is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.

Versnelling van de groei: Unable to compare KA6N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: KA6N is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).

Rendement op eigen vermogen

Hoge ROE: KA6N has a negative Return on Equity (-2.3%), as it is currently unprofitable.

This company listing is no longer active

Karo Pharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karo Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Karo Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)

Recent updates

Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.

Nasdaq Approves Karo Pharma's Application for De-Listing

Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.

Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).

Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karo Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Karo Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others.

Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million.

Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)

Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO).

Independent Chairman of the Board Bo Hansen has left the company

First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021

Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million.

New 90-day low: €4.81

New 90-day low: €5.08

Karo Pharma AB (publ) to Report First Half, 2021 Results on Jul 22, 2021

New 90-day low: €5.38

New 90-day low: €5.87

J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million.

Third quarter 2020 earnings released: kr0.013 loss per share

Third quarter earnings released

EQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion.

Karo Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million.

Karo Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden